Encision (ECIA) Stock Price, News & Analysis

Company Overview

Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.

Key Stats

• Today's Range: $0.37 to $0.37
• 50-Day Range: $0.30 to $0.42
• 52-Week Range: $0.16 to $0.50
• Volume: N/A
• Average Volume: 186 shs
• Market Capitalization: $4.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Encision Stock Analysis - MarketRank™

Encision scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Encision.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Encision is -9.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Encision is -9.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Encision has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Encision has been sold short.

Short Interest Ratio / Days to Cover

Encision has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Encision does not currently pay a dividend.

Dividend Growth

Encision does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Encision has been sold short.

Short Interest Ratio / Days to Cover

Encision has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.7 / 5
• News Sentiment: N/A

News Sentiment

Encision has a news sentiment score of -0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Encision this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Encision insiders have not sold or bought any company stock.

Percentage Held by Insiders

36.75% of the stock of Encision is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.20% of the stock of Encision is held by institutions.

ECIA Stock Analysis - Frequently Asked Questions

How have ECIA shares performed this year?

Encision's stock was trading at $0.45 on January 1st, 2025. Since then, ECIA stock has decreased by 18.7% and is now trading at $0.3660.

How were Encision's earnings last quarter?

Encision Inc. (OTCMKTS:ECIA) announced its quarterly earnings results on Thursday, May, 14th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter. The medical device company earned $1.78 million during the quarter. Encision had a negative trailing twelve-month return on equity of 32.90% and a negative net margin of 8.96%.

How do I buy shares of Encision?

Shares of ECIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Encision own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Encision investors own include Akers Biosciences (AKER), MGT Capital Investments (MGTI), Brainstorm Cell Therapeutics (BCLI), Aviat Networks (AVNW), Activision Blizzard (ATVI), ATI (ATI) and Digital Turbine (APPS).

Company Calendar

• Last Earnings: 5/14/2020
• Today: 7/05/2025
• Next Earnings (Estimated): 7/14/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:ECIA
• CIK: 930775
• Web: www.encision.com
• Phone: (303) 444-2600
• Fax: 303-444-2693
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$690 thousand
• Net Margins: -8.96%
• Pretax Margin: -7.85%
• Return on Equity: -32.90%
• Return on Assets: -15.51%

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 1.67
• Quick Ratio: 0.82

Sales & Book Value

• Annual Sales: $6.59 million
• Price / Sales: 0.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 2.44

Miscellaneous

• Outstanding Shares: 11,880,000
• Free Float: 7,514,000
• Market Cap: $4.35 million
• Optionable: Not Optionable
• Beta: 0.55